Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus isolated limb perfusion for in-transit melanoma metastases
NL-OMON60112Phase 2Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Nivolumab + melphalan-based isolated limb perfusion with Placebo + melphalan-based isolated limb perfusion (2 arms). Primary endpoint: Complete response rate at 3 months. Started Oct 2021; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON60112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60112.